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Metformin hydrochloride (metformin HCl) was formulated as a
hydrophobic matrix sustained release tablet employing wax materials
and the sustained release behavior of the fabricated tablet was
investigated. Sustained release matrix tablets containing 500 mg
metformin HCl were developed using different bees wax
combinations. The tablets were prepared by wet granulation
technique. The formulation was optimized on the basis of
acceptable tablet properties and in vitro drug release. The resulting
formulation produced monolithic tablets with optimum hardness,
uniform thickness, consistent weight uniformity and low friability.
Statistically significant differences were found among the drug
release profile from different bees wax combination matrices. The
results of dissolution studies indicated that formulations F-III, F-
IV and F-V (bees wax and cetyl alcohol combination matrices),
exhibited drug release pattern very close to theoretical release
profile. Applying kinetic equation models, the mechanism of release
of the drug from the three formulations was found to be followed
Higuchi model, as the plots showed high linearity, with correlation
coefficient (R2) value of 0.98 or more. Tablet matrices containing
cetyl alcohol gave better release of the drug than other materials
studied. However, the rate of release varied with amount of cetyl
alcohol in the matrix. The ‘n’ value lies below 0.5 (Korsmeyer-
Peppas model) demonstrating that the mechanism controlling the
drug release was the quasi Fickian. Therefore, the results of the
kinetic study obtained permit us to conclude that the fabricated

















Metformin HCl is a biguanide oral antihyperglycemic
(antidiabetic) agent. It is used as monotherapy as an adjunct
to diet and exercise for the management of type 2 (non-insulin
dependent) diabetes mellitus in patients whose hyperglycemia
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cannot be controlled by diet alone (AFHS Drug Information,
2003a). It is slowly and incompletely absorbed from the
gastrointestinal tract, with its absolute bioavailability reported
to be about 50 to 60% (Sweetman, 2002). It is freely soluble
in water. A traditional oral multiple release formulation
releases the drug with undesirable peaks and troughs. These
drawbacks can be overcome by designing a suitable sustained
release metformin HCl preparation. Recently several studies
have been carried out to investigate the pharmacokinetic and
pharmacodynamic advantages of oral controlled release
products of metformin HCl (Di Colo et al., 2005; Hu et al.,
2006; Balasubramaniam et al., 2007; Basak et al., 2007).
The primary benefit of a sustained release dosage
form, compared to a conventional dosage form, is the
uniform drug plasma concentration and therefore uniform
therapeutic effect. Over the past two decades, sustained
release dosage forms have made significant progress in
terms of clinical efficacy and patient compliance. Matrix
devices, due to their chemical inertness, drug embedding
ability and drug release character, have gained steady
popularity for sustaining the release of a drug.
The objective of this study was to prepare sustained
release metformin HCl tablets using hydrophobic wax
materials, bees wax in combination with glyceryl
monostearate, stearic acid or cetyl alcohol, to evaluate the
in vitro release characteristics and to predict and correlate
the release behavior of metformin HCl from the matrix. In
order to elucidate release kinetics it is necessary to fit drug
release data into a suitable model. The commonly adopted
models for understanding the release of drugs from
matrices are zero-order equation, first-order equation
(Gibaldi, Feldman, 1967; Wagner, 1969), Higuchi equation
(Higuchi, 1963) and Korsmeyer-Peppas simple exponential
equation (Korsmeyer et al., 1983; Peppas, 1985) models.
These simple exponential equation models have been used
to elucidate the mode of release.
MATERIAL AND METHODS
Material
Metformin HCl was obtained from New Drug and
Chemical Company, Mumbai, India. Ethyl cellulose and
stearic acid were purchased from the Dow Chemicals
Company, Michigan, USA. Microcrystalline cellulose
(MCC, Avicel pH 101) and cetyl alcohol were purchased
from Coveral and Company, Chennai, India. Magnesium
stearate and talc were procured from SD Fine Chemicals
Ltd., Mumbai, India. Materials and excipients used in
preparing tablets were Indian Pharmacopoeia grades. All
other ingredients used throughout the study were of
analytical grades and were used as received.
Estimation of metformin HCl
An ultraviolet (UV) spectrophotometric (Shimadzu
1601 UV/VIS spectrophotometer, Kyoto, Japan) method
based on measurement of absorption at 232 nm in water
was used for the estimation of metformin HCl (Indian
Pharmacopoeia, 1996a). The method showed very good
linearity (R2 value 0.9998) in the concentration range of 0
- 20 µg/mL. When standard drug solution was assayed for
number of times (n=6) the relative error (accuracy) and the
relative standard deviation were found to be 0.8% and
0.47% respectively.
Preparation of matrix tablets
Matrix tablets, each containing 500 mg metformin
HCl were prepared by a conventional wet granulation
technique. The composition of various formulations of the
tablets with their codes is listed in Table I. The composition
with respect to polymer combination was selected on the
basis of trial preparation of tablets. The amount of bees
wax was decreased gradually for formulation IV and V and
the reduced amount of bees wax was replaced by cetyl
alcohol. This was done to adjust drug release according
predetermined limits (to be mentioned later). In each
formulation, the amount of the active ingredient is 500 mg
and the total weight of a tablet is 630 mg. A batch of 3000
tablets was prepared with each formula. The ingredients
were passed through a 60 mesh sieve. A blend of all
ingredients except glidant and lubricant was mixed for
8-10 min in a polythene bag. Particular attention had been
given to ensure thorough mixing and phase
homogenization.
TABLE I - Formulae of Metformin HCl SR Matrix Tablets
Ingredients mg/tab. Formulations
F-I F-II F-III F-IV F-V
Metformin HCl 500 500 500 500 500
MCC 15 15 15 15 15
Ethyl cellulose 24 24 24 24 24
Bees wax 50 50 50 42.5 37.5
Glycerin monostearate 30 - - - -
Stearic acid - 30 - - -
Cetyl alcohol - - 30 37.5 42.5
Magnesium stearate 6 6 6 6 6
Talc 5 5 5 5 5
Total 630 630 630 630 630
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Granulation was done manually with a solution of
calculated quantity of ethyl cellulose in sufficient solvent
blend containing isopropyl alcohol and methylene chloride
in 1:1 ratio. The wet masses were passed through a 12 mesh
sieve and the wet granules produced were first air dried for
10 min and finally at 45-50 ºC in a tray drier for 2 hours.
The dried granules were sized by a 20 mesh sieve and mixed
with 8% (150g /batch) of fines (granules passed through a
20 mesh sieve). Magnesium stearate and talc were added as
glidant and lubricant and blended for 10 min in a twin-shell
blender. Granules thus obtained were compressed into
tablets on a 23-station rotary Cadmach machine (Cadmach,
Ahmedabad, India) at a constant compression force using
15/32 mm standard round punches. Just before
compression, the surfaces of the die and punches were
lubricated with magnesium stearate. All the tablets were
stored in airtight containers for further study. Prior to
compression, granules were evaluated for their flow and
compressibility characteristics.
Evaluation of granules
Angle repose (θ) of granules was determined by the
funnel method. The diameter and height of the powder cone
were measured and angle of repose was calculated using the
equation (Carter, 1986), Tan θ = h/r, where h and r are the
height and radius of the powder cone. Both loose bulk
density (LBD) and tapped bulk density (TBD) were
determined. LBD and TBD were calculated using the
equations (Shah et al., 1997), LBD = weight of the powder/
volume of the packing; TBD = weight of the powder/tapped
volume. The compressibility index of the granules was
determined by Carr’s index (Carr, 1965) using the
equation, Carr’s index = [(TBD-LBD) X 100)]/TBD.
Evaluation of tablets
The prepared matrix tablets were evaluated for
hardness, weight variation, thickness, friability and drug
content. Hardness of the tablets was tested using a Strong-
Cobb hardness tester (Tab-machine, Mumbai, India).
Friability of the tablets was determined in a Roche
friabilator (Campbell Electronics, Mumbai, India). The
thickness of the tablets was measured by vernier caliper.
Weight variation test was performed according to the
official method (Indian Pharmacopoeia, 1996b).
In vitro drug release studies
In vitro drug release from tablets was studied using
a USP 24 dissolution apparatus type 2 (USP 2000) (Tab-
Machine, Mumbai, India) at 100 rpm. The study was
carried out in 900 mL 0.1N HCl at 37±0.5 ºC for first 2
hours and then in 900 mL of phosphate buffer (pH 6.8)
TABLE III - Properties of compressed metformin matrix tablets
Formulation Weight Hardness Thickness Friability Drug content
mg ± SD (n=20) kg/cm2 ± SD (n=3) mm ± SD (n=5) % % ± SD (n=3)
F-I 632.3 (2.53) 4.2 (0.30) 5.56 (0.05) 0.68 98.60 (0.23)
F-II 629.4 (2.97) 3.7 (0.10) 5.24 (0.04) 0.59 99.70 (0.17)
F-III 630.9 (1.83) 4.7 (0.20) 5.15 (0.07) 0.45 97.37 (0.42)
F-IV 633.6 (3.53) 5.1 (0.31) 5.51 (0.02) 0.61 97.92 (0.23)
F-V 632.6 (2.21) 4.1 (0.21) 5.50 (0.06) 0.62 101.05 (0.35)
All figures in the parentheses represent ±SD; n is specified in each column head
TABLE II - Properties of the granules
Formulation Angle of repose Tapped bulk Loose bulk Compressibility
density (g/mL) density (g/mL) index
F-I 32.80 (0.07) 0.645 (0.05) 0.492 (0.07) 22.92 (0.09)
F-II 30.06 (0.09) 0.636 (0.03) 0.496 (0.04) 21.97 (0.10)
F-III 31.33 (0.05) 0.632 (0.07) 0.502 (0.05) 20.86 (0.11)
F-IV 32.97 (0.11) 0.641 (0.04) 0.501 (0.07) 21.54 (0.06)
F-V 29.06 (0.13) 0.637 (0.08) 0.498 (0.03) 21.86 (0.09)
Figures in the parentheses represent ±SD, n=3
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from 3 to 8 hours. Sink condition was maintained for the
whole experiment. Ten millilitres of the sample was
withdrawn at regular intervals and the same volume of pre-
warmed (37±0.5 ºC) fresh dissolution medium was
replaced to maintain the volume constant. The samples
withdrawn were filtered through a 0.45 µ membrane filter
(Nunc, New Delhi, India) and the drug content in each
sample was analyzed after suitable dilution with a
Shimadzu 1601 UV/VIS spectrophotometer (Kyoto,
Japan) at 232 nm. The content of metformin HCl was
calculated taking 798 as value A (1%, 1 cm) at 232 nm. The
predetermined drug release requirement, based on a method
described earlier (Basak et al. 2004) and in order to provide
theoretical release of metformin HCl (calculated using
available pharmacokinetic data) (AHFS Drug Information
2003b, Scheen 1996) was set at between 30-50% at 1 hour,
between 45-65% at 3 hours, between 60-85% at 6 hours
and not less than 80% at 8 hours. The dissolution test was
repeated thrice. Drug dissolved at specified time periods
was plotted as cumulative percent release versus time
(hours) curve.
Analysis of release data
The release data obtained were treated according to
zero-order (cumulative amount of drug release versus
time), first-order (log cumulative percentage of drug
remaining versus time), Higuchi (cumulative percentage of
release versus square root of time) and Korsmeyer-Peppas
(log cumulative percentage of drug released versus log
time) equation models.
RESULTS AND DISCUSSION
The results for angle of repose and compressibility
index ranged from 29.06±0.13 to 32.97±0.11 and
20.86±0.11 to 22.92±0.09 respectively (Table II). An angle
of repose of less than 30 degrees indicates good flow
properties (Aultron, 1998). This was further supported by
the lower compressibility index. Granules with Carr’s
index values around 21% and below are considered to have
fair and excellent flow properties (Aultron, 1998). Table III
gives the physical parameters (hardness, and thickness,
friability) and weight uniformity of all the fabricated
tablets. Table III also shows the drug content of these
tablets. The tablet formulations in all the batches prepared
contained metformin HCl within 100 ± 5% of labeled
content. All the tablet formulations showed acceptable
pharmacotechnical properties and complied with
pharmacopoeial specifications for weight variation and
friability (less than 0.7%).
In the trial study to determine the optimum
concentration of hydrophobic wax material (s) to release
drug with predetermined level, a range of 75 to 85 mg
combined materials consisting of bees wax and other
hydrophobic material per tablet with 4% w/v ethyl cellulose
as granulating agent showed good consistency, with desired
sustained release. The attempt to increase amount of cetyl
alcohol and reduce bees wax in F-IV and F-V, resulted
improved drug release. This is due to the better matrix
erosion by the cetyl alcohol resulting from higher water
penetration in the matrix. Stearic acid or cetyl alcohol in
combination with bees wax provides the necessary physical
characteristics to form an easily compressible matrix tablet.
The results of dissolution studies of formulations F-I
and F-II are shown in Figure 1. Tablets F-I, and F-II released
59.70±1.03% and 54.2±2.26% respectively, of their
metformin HCl content at the end of 2 hours. Each data point
in the dissolution profile represents the mean of three
determinations. Both the two values of percentage release at
2 hours in the different batches differed significantly (single
factor ANOVA) at P < 0.01 (DF=2, F=14.71). Formulations
F-I and F-II, containing bees wax in combination of glycerin
monostearate or stearic acid, failed to sustain release beyond
72% at the end of 8 hours. These formulations remained
impermeable, probably due to less water penetration in the
matrix. Figure 2 indicates that F-III, F-IV and F-V released
45.70±0.50%, 51.3±1.20%, and 57.6±1.32% of metformin
HCl at the end of 2 h and 78.0±0.61%, 85.33±1.50%, and
92.1±1.4 % at the end of 8 hours, respectively. Formulation
III failed the drug release requirements at the end of 8 hours
by just 2%. The differences between 2 hours release values
for F-III, F-IV and F-V were significant at P< 0.001(DF=2,
F= 92). Significant differences were observed between 8
hours release values (P<0.001, DF=2 and F=88).
TABLE IV - In vitro release kinetic values of metformin
from selected formulations
Formulation First Higuchi2 Zero Korsmeyer-
order1 order3 Peppas4
R2 R2 R2 R2 n
F-I 0.7496 0.7923 0.6817 0.8800 0.296
F-II 0.8494 0.8933 0.8027 0.9413 0.272
F-III 0.9653 0.9835 0.9747 0.9804 0.332
F-V 0.9792 0.9925 0.9661 0.9634 0.361
F-VI 0.9643 0.9941 0.9497 0.9686 0.382
1First order equation, log Q = log Q0 – kt/2.303, 
2Higuchi
equation, Q = k t½, 3Zero order equation, Q = Q + k t,
4Korsmeyer-Peppas equation, Qt/Qµ = kt
n
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Incorporation of higher amount of cetyl alcohol in F-IV and
F-V was found to be more suitable to give good drug release
characteristics.
The dissolution data (from the values of 1 to 8 hours
drug release) of all batches were fitted to first-order,
Higuchi, zero-order and Korsemeyer-Peppas models. As
clearly indicated in figure 1 and figure 2, the formulations
didn’t follow zero-order release kinetics. The model that
best fitted the release data was evaluated by correlation
coefficient (R2). R2 values for all formulations in various
models are given in Table IV. When the data were plotted
according to a first-order equation, the formulations F-III,
F-IV and F-V showed a fair linearity, with regression
values 0.9653, 0.9792 and 0.9643. The best fit with higher
correlation (R2> 0.98) was found with the Higuchi’s
equation for F-III, F-IV and F-V formulations. Release of
a drug from a hydrophobic matrix tablet generally involves
both pore diffusion and matrix erosion. Dissolution yielded
incomplete drug release, probably due to coating of certain
fraction of drug by waxy material, no clear inference could
be made regarding the kinetics of the drug release from
formulations F-I and F-II. The release profiles of F-III, F-
IV and F-V could be best explained by Higuchi model, as
the plots showed high linearity, with correlation coefficient
(R2) values 0.9835, 0.9925 and 0.9841 respectively. The
diffusion mechanism of drug release was further confirmed
by Korsmeyer-Peppas plots that showed fair linearity (R2
values between 0.96 and 0.98), with slope values less than
0.5, indicating that drug release mechanism from the
selected tablets was diffusion controlled. This finding was
in accordance with other reported works (Goodhart et al.,
1974; Peterlin, 1980; Reza et al., 2002).
CONCLUSION
The approach of the present study was to make an
evaluation of wax materials as sustained release matrix for
water soluble drug, metformin HCl and to assess the
kinetics of drug release mechanism. Bees wax and cetyl
alcohol can be used for sustained release of metformin HCl.
The mechanism of drug release from wax matrices has been
a matter of controversy since wax matrices tend to be more
heterogeneous than other matrices (Dakkuri A et al. 1978).
The study reveals that, the release of water soluble drug,
metformin HCl exhibited diffusion dominated mechanism.
The wax and cetyl alcohol ratio plays an important role in
overall release of the drug. The hydrophobic wax matrix
tablet is a promising approach to achieve appropriate
sustained release dosage.
RESUMO
Planejamento e características de liberação de com-
primidos de liberação controlada de cloridrato de
metformina
O cloridrato de metformina (metformina.HCl) foi formula-
do como comprimido de liberação controlada, empregan-
do materiais cerosos como matriz hidrofóbica, e o compor-
tamento dessa formulação foi investigado. Comprimidos
com matriz de liberação controlada contendo 500 mg de
metformina.HCl foram desenvolvidos usando diferentes
combinações de cera de abelha. Os comprimidos foram
preparados pela técnica de granulação por via úmida. A
FIGURE 1- In vitro release profiles of metformin from batches
F-I and F-II matrix tablets. In vitro cumulative release of
metformin from formulation F-I (– –), F-II (– –). Each point
represents mean ± SD, n=3
FIGURE 2- In vitro release profiles of metformin from
batches F-III, F-IV and F-V matrix tablets. In vitro
cumulative release of metformin from formulation F-III (–
–), F-IV (– –) and F-V (– –). Each point represents mean
± SD, n=3
S. C. Basak, K. S. Kumar, M. Ramalingam482
formulação foi otimizada com base nas propriedades acei-
táveis do comprimido e na liberação in vitro. A formulação
resultante produziu comprimidos monolíticos, com dureza
ótima, uniformidade de espessura, uniformidade de peso e
baixa friabilidade. Encontraram-se diferenças significati-
vas no perfil de liberação do fármaco de diferentes combi-
nações de cera de abelha. Os resultados dos estudos de dis-
solução indicaram que as formulações F-III, F-IV e F-V
(matrizes de combinações de cera de abelha e álcool
cetílico) exibiram padrão de liberação de fármaco muito
próxima do perfil teórico. Aplicando modelos de equações
cinéticas, o mecanismo de liberação de fármacos das três
formulações seguiu o modelo de Higuchi, uma vez que se
observou alta linearidade, com coeficiente de correlação
(R2) de 0,98 ou maior. As matrizes dos comprimidos conten-
do álcool cetílico permitiram melhor liberação do fármaco
do que aqueles dos outros materiais estudados. Entretan-
to, a velocidade de liberação variou com a quantidade de
álcool cetílico na matriz. O valor “n” ficou abaixo de 0,5
(modelo de Korsmeyer-Peppa), demonstrando que o meca-
nismo que controla a liberação foi quase Fickiano. Assim,
os resultados do estudo cinético permitiram concluir que os
comprimidos fabricados com matriz hidrofóbica, nesse
caso, liberam o fármaco por meio de mecanismo de difusão.
UNITERMOS: Metformina.HCl. Matrizes hidrofóbicas.
Fármaco/liberação controlada. Modelo cinético. Equa-
ção de Higuchi.
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